Atty Docket No. 02307K-026726US

PTO FAX NO.: 1-571-273-8300

ATTENTION:

Examiner ALLEN, MARIANNE P

Group Art Unit 1646

OFFICIAL COMMUNICATION FOR THE PERSONAL ATTENTION OF EXAMINER ALLEN, MARIANNE P

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Lewis T. Williams, et al., Application No. 10/027,400, filed December 19, 2001 for HUMAN PLATELET-DERIVED GROWTH FACTOR RECEPTORS are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

Supplemental Amendment Under 37 CFR 1.116 1.

Number of pages being transmitted, including this page: 4

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FAC\$IMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor

San Francisco, CA 94111-3834 Telephone: 415-576-0200

Fax: 415-576-0300

0106

60722345 v1

RECEIVED
CENTRAL FAX CENTER

MAR 1 4 2006

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on MACCO 17, 2006

TOWNSEND and TOWNSEND and CREW LLP

By: Drietanior Clough

SUPPLEMENTAL AMENDMENT UNDER 37 CFR 1.116 EXPEDITED PROCEDURE – EXAMINING GROUP 1646

PATENT

Attorney Docket No.: 02307K-026726US Client Ref. No.: 88-001-A Con

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lewis T Williams et al.

Application No.: 10/027,400

Filed: December 19, 2001

For: HUMAN PLATELET-DERIVED GROWTH FACTOR RECEPTORS

Customer No.: 20350

Confirmation No. 2440

Examiner:

ALLEN, MARIANNE P

Technology Center/Art Unit: 1646

SUPPLEMENTAL AMENDMENT UNDER 37 CFR 1.116 EXPEDITED

PROCEDURE EXAMINING GROUP 1646

Mail Stop AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Further to the amendment dated February 17, 2006 in response to the Final Office Action mailed October 27, 2005 in the above-referenced application, please enter the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.